There's nothing bearish at all about what it reported recently.Sometimes with biotech stocks, what a company considered to be good news clashes with what the market is expecting. That was true on Oct. 24 when Intellia Therapeutics (NTLA 2.56%) announced some positive new clinical trial data only to see its stock slide by 18% -- and the price hasn't fully recovered as of yet.What's causing this disconnect, and could Intellia Therapeutics be a buy now? We'll start by answering the first question.A competitor' ...